About two and a half months have passed since my last article , "Regeneron Pharmaceuticals: My Highest Conviction Pharmaceutical Pick for 2025," and during that time, its stock price has risen by 2.5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical compan ...